GlassScriptPhysician profile
Jeffery Bollenbacher
NPI 1952458580
$10,582.51
in general payments reported to CMS, 2019-2025
35 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $245 · 2021: $623 · 2022: $4,988 · 2023: $3,079 · 2024: $300 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Travel and Lodging: $1,569 · Consulting Fee: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.19 |
| Travel and Lodging | $1,568.99 |
| Consulting Fee | $578.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,951.93 | 2019-2025 | Blueprint Patient Specific Instrumentation, Inspace, Aequalis Perform Reversed |
| Arthrex, INC. | $2,896.68 | 2022 | |
| Zimmer Biomet Holdings, INC. | $1,574.96 | 2019-2022 | |
| Crossroads Orthopedics, LLC | $815.49 | 2022-2023 | |
| Catalyst Orthoscience | $669.66 | 2021-2023 | Catalyst Total Csr |
| Pfizer INC. | $248.47 | 2019-2021 | |
| Acumed LLC | $175.01 | 2025 | Acumed |
| Anika Therapeutics, INC. | $153.56 | 2025 | Tactoset |
| Orthofix Medical, INC. | $113.35 | 2022-2025 | Physio-Stim |
| Amgen INC. | $109.41 | 2021-2025 | Evenity, Prolia |
| Bioventus LLC | $100.52 | 2019-2023 | Durolane |
| Pacira Therapeutics, INC. | $96.18 | 2020-2021 | |
| Depuy Synthes Sales INC. | $84.12 | 2019-2022 | |
| Avanos Medical | $76.37 | 2020-2023 | On-Q* Pump and Accessories |
| Pacira Pharmaceuticals Incorporated | $52.92 | 2023-2024 | Exparel, Zilretta, Iovera |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carbofix Orthopedics INC | $50.12 | 2024 | |
| Smith+Nephew, INC. | $45.32 | 2020-2021 | |
| Baudax Bio INC. | $45.03 | 2021-2022 | |
| Horizon Therapeutics Plc | $35.87 | 2023 | Krystexxa |
| Davol INC. | $26.13 | 2020 | |
| Djo, LLC | $23.85 | 2023 | Donjoy |
| Heron Therapeutics, INC. | $23.45 | 2023 | Zynrelef |
| Irhythm Technologies, INC. | $23.11 | 2023 | Zio Xt Patch |
| Xeris Pharmaceuticals, INC. | $22.23 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.97 | 2025 | |
| Orthogenrx INC. | $16.93 | 2019 | |
| Medwest Associates | $16.00 | 2023 | |
| Novo Nordisk INC | $15.82 | 2023 | Rybelsus |
| Merck Sharp & Dohme LLC | $15.73 | 2025 | Bridion |
| Ossur Americas, INC. | $14.89 | 2024 | Miami J |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2023 | Seglentis |
| Medline Industries LP | $13.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.73 | 2021 | |
| Convatec INC. | $13.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Bollenbacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.